Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties

Antibody-based therapeutics represent an important class of biopharmaceuticals in cancer immunotherapy. CD3 bispecific T-cell engagers activate cytotoxic T-cells and have shown remarkable clinical outcomes against several hematological malignancies. The absence of a costimulatory signal through CD28...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsayed, Abdullah, Pellegrino, Christian, Plüss, Louis, Peissert, Frederik, Benz, Ramon, Ulrich, Franziska, Thorhallsdottir, Gudrun, Plaza, Sheila Dakhel, Villa, Alessandra, Mock, Jacqueline, Puca, Emanuele, De Luca, Roberto, Manz, Markus G., Halin, Cornelia, Neri, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251795/
https://www.ncbi.nlm.nih.gov/pubmed/37288872
http://dx.doi.org/10.1080/19420862.2023.2220839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251795/
https://www.ncbi.nlm.nih.gov/pubmed/37288872
http://dx.doi.org/10.1080/19420862.2023.2220839

Ejemplares similares